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Major depressive disorder (MDD) is clinically heterogeneous with prevalence rates twice as 
high in women as in men. There are many possible sources of heterogeneity in MDD most of 
which are not measured in a sufficiently comparable way across study samples. Here, we 
assess genetic heterogeneity based on two fundamental measures, between-cohort and 
between-sex heterogeneity. First, we used genome-wide association study (GWAS) 
summary statistics to investigate between-cohort genetic heterogeneity using the 29 
research cohorts of the Psychiatric Genomics Consortium (PGC; N cases = 16,823, N controls 
= 25,632) and found that some of the cohort heterogeneity can be attributed to 
ascertainment differences (such as recruitment of cases from hospital vs. community 
sources). Second, we evaluated between-sex genetic heterogeneity using GWAS summary 
statistics from the PGC, Kaiser Permanente GERA, UK Biobank, and the Danish iPSYCH 
studies but did not find convincing evidence for genetic differences between the sexes. We 
conclude that there is no evidence that the heterogeneity between MDD data sets and 
between sexes reflects genetic heterogeneity. Larger sample sizes with detailed phenotypic 
records and genomic data remain the key to overcome heterogeneity inherent in 
assessment of MDD. 
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1 INTRODUCTION 
Major depressive disorder (MDD) is a common debilitating disorder with lifetime risk of 
~15% (Kessler & Bromet, 2013; Lohoff, 2010). Genetic factors contribute to etiology of MDD 
with heritability estimated to be ~37% (Kendler, Gatz, Gardner, & Pedersen, 2006; Sullivan, 
Neale, & Kendler, 2000) of which about one-third is tracked by common-genetic variants 
(Cross-Disorder Group of the Psychiatric Genomics et al., 2013; Wray et al., 2018). 
Nongenetic factors also contribute and environmental risk factors include childhood 
psychological trauma (Chapman et al., 2004; Heim, Newport, Mletzko, Miller, & Nemeroff, 
2008; Vythilingam et al., 2002), social isolation (Bruce & Hoff, 1994), and medical conditions, 
such as cardiovascular disease (Fiedorowicz, 2014; Fraguas et al., 2007; Huffman, Celano, 
Beach, Motiwala, & Januzzi, 2013). Most complex disorders are considered to be 
heterogeneous at clinical presentation. For MDD, heterogeneity is inherent in the diagnostic 
framework since diagnosis is achieved through different combinations of endorsements of 
at least five out of nine criteria in the context of depressed mood for most of the day every 
day for 2 weeks (Diagnostic and Statistical Manual of Mental Disorders 
[DSM] criteria). Heterogeneity in symptom profiles between individuals reflects not only the 
symptoms endorsed, but for some criteria (those assessing sleep, weight/appetite, and 
psychomotor function) the endorsement can reflect either increase or decrease (or both). 
It is plausible that these clinical differences reflect different biological pathways. The lack of 
a biological ͞gold standard͟ definition in psychiatric illness is well recognized (Kapur, 
Phillips, & Insel, 2012), and a key question for the field is whether genetic heterogeneity 
underpins phenotypic heterogeneity (Fanous & Kendler, 2005), and if genome-wide genetic 
data can support analyses that demonstrate genetic heterogeneity (Han et al., 2016). Here, 
we assess genetic heterogeneity based on two fundamental measures available to us, 
between-cohort and between-sex heterogeneity. While nonbiological factors (such as 
ascertainment strategy) could contribute to both between-cohort and between-sex 
heterogeneity, evidence for between-sex heterogeneity may reflect, at least in part, 
biological differences. 
Prevalence rates of MDD in women that are double those of men are consistently reported 
in epidemiological studies, with lifetime risk approximately 0.2 for females and 0.1 for males 
(Kessler, 2003). Women tend to have younger age of onset, greater comorbidity with panic 
and other anxiety disorders, whereas men exhibit stronger comorbidity with alcohol 
dependence or abuse (Schuch, Roest, Nolen, Penninx, & de Jonge, 2014). Attempts to link 
the epidemiological differences to biological differences have been less consistent. Some 
twin studies reported significantly higher heritability in females (0.42, 95% CI = 0.36–0.47) 
than males (0.29, 95% CI = 0.19–0.38), and with genetic correlation significantly different 
from 1 (rg~0.60, 95% CI = 0.31–0.99) (Kendler et al., 2006). Other studies failed to find 
differences between sexes (Fernandez-Pujals et al., 2015). Drawing strong conclusions may 
be confounded by reporting biases as males are more likely to underreport their symptoms 
when compared to females (Hunt, Auriemma, & Cashaw, 2003; Thornicroft et al., 2017). 
We use genome-wide association study (GWAS) summary statistics data to investigate 
genetic heterogeneity of MDD. We study between-cohort genetic heterogeneity using data 
from the 29 independent studies that comprise the Wave 2 PGC-MDD study (PGC29 [Wray 
et al., 2018]). We also investigate genetic heterogeneity by sex using GWAS summary 
statistics from PGC29 and three other large data sets. We evaluate between-cohort and 
between-sex genetic heterogeneity estimates of SNP-heritabilities and genetic correlations. 
These estimates of genetic parameters, calculated from genome-wide data, provide single 
statistic summaries of the data. Specifically, differences in SNP-heritability estimates 
between samples could imply real differences in the relative magnitude of genetic risk effect 
sizes between samples or could reflect biases due to ascertainment characteristics of the 
sample. In contrast, an estimate of a genetic correlation less than one may reflect 
differences in the relative ordering of genetic risk effects between samples. It is possible for 
SNP-heritabilities to differ between samples but the genetic correlations to be one. 
 
2 MATERIALS AND METHODS 
2.1 Between-cohort heterogeneity 
We investigate heterogeneity between cohorts from the PGC Working Group for MDD (PGC-
MDD) (Major Depressive Disorder Working Group of the Psychiatric et al., 2013), which 
comprises 29 cohorts (PGC29, 10 from Wave 1 (Major Depressive Disorder Working Group 
of the Psychiatric et al., 2013) and 19 from Wave 2 (Wray et al., 2018)), totaling 16,815 cases 
(68% female) and 25,485 controls (51% female) (Table 1, Supporting Information Table S1). 
Cohorts represent individual studies in which cases and controls were imputed together to 
the 1,000 Genomes reference panel (Genomes Project et al., 2010) from a common set of 
SNPs that had been processed through a common quality control (QC) pipeline (Wray et al., 
2018). For the majority of cohorts (but not all), cases and controls were collected by the 
same research group and were genotyped together on the same genotyping array. All 
29 case cohorts passed a structured methodological review by MDD assessment experts (DF 
Levinson and KS Kendler). Cases were required to meet international consensus criteria 
(DSM-IV, International Statistical Classification of Diseases [ICD]-9, or ICD-10) (American 
Psychiatric Association, 1994; World Health Organization, 1978, 1992) for a lifetime 
diagnosis of MDD established using structured diagnostic instruments from assessments by 
trained interviewers, clinician-administered checklists, or medical record review. 
Nonetheless, there were differences in ascertainment across cohorts (Supporting 
Information Table S1). For example, the RADIANT cohort (rad3) (Lewis et al., 2010) recruited 
cases of clinically assessed recurrent MDD, which being more severe have lower lifetime risk 
~5% (McGuffin, Katz, Watkins, & Rutherford, 1996), compared to community samples such 
as the QIMR cohorts (qi3c, qi6c, and qio2) assessed by self-report interview and with 
lifetime risk ~24% (Mosing et al., 2009). To capture heterogeneity due to ascertainment, we 
coded the 29 cohorts as identified in community, psychiatric outpatient, psychiatric 
inpatients, or mixed in−/out-patient settings (Supporting Information Table S1). 
 
2.2 Between-sex heterogeneity 
We investigate between sex heterogeneity using four large MDD data sets (Table 1). In 
addition to PGC29, we used the Genetic Epidemiology Research on Adult Health and Aging 
(GERA) Cohort (Banda et al., 2015) (where electronic medical records from the Kaiser 
Permanente healthcare system were used to identify cases as individuals being treated  for 
any psychiatric disorder), the Danish iPSYCH cohort (where national hospital records 
identified cases as those ever treated clinically for MDD and controls as those who have 
not), and the volunteer UK Biobank (Bycroft et al., 2018; Lane et al., 2016) (UKB) study. UKB 
cases were those with either recorded ICD10 codes for MDD (F32, F33) or self-report for 
seeking treatment for nerves, anxiety or depression; for detailed description of the ͞broad 
depression͟ definition see reference (Howard et al., 2018). Exclusions for both cases  and 
controls were those with recorded schizophrenia, bipolar or mental retardation diagnoses 
or prescriptions associated with these disorders. Additional exclusions for controls included 
those with recorded anxiety, phobic or autistic spectrum disorders. In all studies, cases and 
controls were unrelated. GWAS summary statistics for each cohort used the same methods 
as for PGC29. 
 
2.3 Statistical methods 
We use GWAS summary statistics and linkage disequilibrium (LD) score analysis (LDSC) 
(Bulik-Sullivan et al., 2015) to estimate the total proportion of variance in liability 
attributable to SNPs genomewide (i.e., SNP-heritability). Bivariate LDSC was used to 
estimate the genetic correlation tagged by genome-wide SNPs (rg) between two traits. LDSC 
has been applied widely to GWAS summary statistics of psychiatric (Anttila et al., 2018) and 
other disorders (Bulik-Sullivan et al., 2015), and results have been shown to agree well with 
estimates made from full individual-level genotype and phenotype data using linear mixed 
model analysis (e.g., GREML [Yang et al., 2010]), as long as the LD reference sample is drawn 
from a population that appropriately reflects the samples contributing the GWAS summary 
statistics for each cohort used the same methods as for PGC29. 
 
2.3 Statistical methods 
We use GWAS summary statistics and linkage disequilibrium (LD) score analysis (LDSC) 
(Bulik-Sullivan et al., 2015) to estimate the total proportion of variance in liability 
attributable to SNPs genomewide (i.e., SNP-heritability). Bivariate LDSC was used to 
estimate the genetic correlation tagged by genome-wide SNPs (rg) between two traits. LDSC 
has been applied widely to GWAS summary statistics of psychiatric (Anttila et al., 2018) and 
other disorders (Bulik-Sullivan et al., 2015), and results have been shown to agree well with 
estimates made from full individual-level genotype and phenotype data using linear mixed 
model analysis (e.g., GREML [Yang et al., 2010]), as long as the LD reference sample is drawn 
from a population that appropriately reflects the samples contributing the GWAS summary 
statistics (Yang et al., 2015). A key advantage of LDSC is the minimal computational 
requirements compared to methods that use individual level data, and the ability to 
differentiate between genomic inflation due to polygenicity and due to population 
stratification. Disadvantagesof LDSC are that standard errors (s.e.) of estimates can be 
(about 50%) higher compared to when estimates are based on full data, particularly for rg 





SNP-heritability is estimated on the observed binary scale h2 SNP − cc, but these estimates 
depend on the proportion of cases in the sample (P) and so are not easily comparable across 
cohorts. Hence, for improved interpretability and comparison across studies, h2 
SNP − cc is transformed to the liability scale h2 SNP (Lee, Wray, Goddard, & Visscher, 2011) 






where z is the height of the standard normal density function when truncated at proportion 
K. However, this transformation assumes that controls are screened. Peyrot, Boomsma, 
Penninx, and Wray (2016) showed that when the proportion of controls that are unscreened 
is u, then transformation should be 
  
 
which reduces to Equation 1 when all controls are screened, u = 0. When diseases are 
uncommon, assuming controls are screened when they are not makes little impact (Peyrot 
et al., 2016). However, for very common disorders, such as MDD, the difference is not 
trivial. For example, for K = 0.15, h2 SNP − cc = 0.15, P = 0.5, then h2 SNP= 0.18 when 
controls are screened and 0.24 when unscreened. The rg estimates are robust to P, K, and u, 
since these factors contribute to both numerator and denominator of the correlation (which 
is defined as the estimate of the additive genetic covariance divided by the product of the 
square root of the SNP-heritabilities for the two traits). Hence rg estimates are robust to 
ascertainment practices and approximately the same where estimated on the case–control 
observed scale or liability scales (Bulik-Sullivan, Finucane, et al., 2015). If the same genetic 
effects contribute to disease risk between sexes or between cohorts then rg is expected to 
be 1. It was not possible to compare h2 SNP of each PGC29 cohort, because the per-cohort 
estimates had high s.e. (e.g., a cohort of 500 cases and 500 controls would be expected to 
produce h2 SNP with standard error of at minimum 0.38 [Visscher et al., 2014]). Instead we 
estimated the h2 SNP attributed to a cohort by evaluating its contribution to h2 SNP 
estimates calculated from 500 random samplings of cohorts drawn from the 29 PGC29 
cohorts. In each sampling, we randomly selected cohorts until the total sample size was 
≥5,000, then used the GWAS summary statistics meta-analyzed (weighted by s.e.) in LDSC to 
estimate h2 SNP assuming lifetime risk of K = 0.15, and assuming controls are screened 
(Equation 1). To determine the contribution to the h2 SNP estimate from each cohort we 
fitted a linear model with estimated h2 SNP as the dependent variable regressed on 
indicator variables set as 1 if the cohort contributed to the estimate (was included in the 
random sampling), and 0 otherwise. 
 
3 RESULTS 
3.1 Between-cohort heterogeneity within PGC29 
We estimated h2 SNP in 500 random samplings of the cohorts from PGC29. From a linear 
regression of h2 SNP on indicator variables set as 1 if the cohort contributed to the estimate 
and 0 if it did not, we estimated an h2 SNP effect size deviation per cohort (y-axis Figure 1). 
Fifteen of the 29 cohorts had h2 SNP deviations different from zero (p < 0.05/29). We found 
that the cohorts nes1 (combined sample of the Netherlands Study of Depression and 
Anxiety and the Netherlands Twin Registry) (Boomsma et al., 2008; Penninx et al., 2008) and 
gep3 (GenPod/NEWMEDS) (Lewis et al., 2011) contributed most to variation in estimates of 
h2 SNP, and explain 0.14 and 0.16, respectively, of the variance in h2 SNP estimates across 
the 500 samplings. Samplings that included cohort nes1 had the highest average estimates 
of h2 SNP, while samplings including gep3 had the lowest average estimates. These 
differences are in line with expectations based on screening strategies for controls 
(Supporting Information Table S1). The nes1 cohort used super-screened controls 
(Boomsma et al., 2008), such that controls never scored higher than 0.65 on a general factor 
score for anxious depression (mean = 0, SD = 0.7) derived from a combined measure of 
neuroticism, anxiety, and depressive symptoms assessed via longitudinal questionnaires 
over 15 years. In contrast, the gep3 cohort was a case-only research cohort which was 
matched to independently collected and genotyped controls (hence particularly stringent 
QC is needed to combine the genotype data of the contributing cases and controls). 
In fact, gep3 is one of seven cohorts for which controls were unscreened for MDD (Figure 1), 
but only one other cohort used independently genotyped controls (STAR*D, coded as stm2); 
together the seven cohorts have lower mean beta-values, but not significantly so (p = 
0.055). The trend in these results might be explained by recognizing that SNPheritability is 
first estimated on the observed binary case–control scale h2 SNP − cc and then transformed 
to the liability scale h2 SNP. Indeed, we find that increasing sample prevalence (P in 
Equation 1) is significantly associated with the estimated h2 SNP (p = 0.00057), but not sex 
ratio (p = 0.72). The application of the standard transformation (Equation 1), as we have 
done, assumes screened controls and could generate an underestimate of the SNP-
heritability if controls were in fact unscreened. Similarly, super-screening of controls could 
generate an over-estimate of the true h2 SNP. Hence, we expect that the standard 
transformation would generate an overestimate for the nes1 cohort (super-screened 
controls) and an underestimate for cohorts with unscreened controls, consistent with our 
results. Next, we investigated if h2 SNP estimates differed based on the research protocol to 
ascertain cases. For the same proportion of cases and controls in the GWAS sample, we 
would expect the h2 SNP − cc to be higher for a clinically ascertained cohort than a 
community ascertained cohort, further we would expect the transformation based on K = 
0.15 (Equation 1) to overestimate h2 SNP when the true K is lower (clinical cohort) and 
underestimate h2 SNP when the true K is higher (community cohort). There is evidence to 
support this hypothesis (Figure 1). We found significant difference between the mean 
estimates of community (−0.027, s.e. 0.007) vs noncommunity cohorts (−0.08 s.e. 0.006) 
(with noncommunity comprising the three in- and out-patient categories), using a one-
sided, two-sample t test assuming unequal variance (p = 0.028) (Supporting Information 
Table S4). The difference became more significant (p = 0.015) when the cohorts we had a 
priori reason to exclude, namely nes1 and gep3, based on discussions above were removed. 
 
 
FIGURE 1 Cohort deviation estimates from the linear regression of 
h2 SNP estimates (from each of the 500 samplings of cohorts) on cohort indicator variables 
set at 1 if the cohort was included in the sampling that generated the h2 SNP and 0 
otherwise. In each sampling, cohorts were selected at random until the total case/control 
sample size exceeded 5,000. Cohort GWAS results were meta-analyzed and these results 
passed into LDscore. h2 SNP was estimated using Equation 1 transformation (K = 0.15) 
which assumes controls are screened. h2 SNP estimates of samplings were highest, on 
average, when cohort nes1 was included and lowest, on average, when cohort gep3 was 
included. Wave 1 cohorts have an asterisk by their name and cohorts that have unscreened 
controls are marked by a tilde. Continuous lines around data-points are 95% confidence 




3.2 Between-sex heterogeneity 
Using the four large data sets (Table 1) we investigate sex-specific heterogeneity. We used 
bivariate LDSC to estimate the rg between all pairs of the two sexes by four data sets, but 
the standard errors were high (Supporting Information Table S2). rg involving the GERA_M 
data set were not estimable, because of the negative/zero of h2 SNP used in the 
denominator of the rg estimate. The between-sex rg estimated from the meta-analysis of 
the GWAS summary statistics of the 4 data sets was 0.86 (s.e. 0.04; pH0:rg=1= 3.0 × 10-4), 
and the meta-analysis of 12 male–female rg estimates was 0.76 (s.e. 0.03; pH0:rg = 1 = 8.9 × 
10−16). At face value these results imply genetic factors are only partially shared between 
the sexes. However, this interpretation should be considered with caution when 
benchmarked by the meta-analysis of 6 female–female rg estimates of 0.72 (s.e. 0.04; 
pH0:rg = 1 = 4.9 × 10−11) and the metaanalysis of 3 male–male rg estimates of 0.71 (s.e. 
0.11; pH0:rg = 1 = 0.11) Hence, the between-sex estimate of rg being significantly different 
from zero likely reflects the general heterogeneity between the data sets rather than being 
sex-specific. Next, we investigated sex-specific estimates of h2 SNP using LDSC (Table 2, 
Supporting Information Table S3) to determine if there is evidence for a greater genetic 
contribution to MDD risk in females then males. We have power to detect differences of the 
order of 2*(s.e. of male estimate + s.e. of female estimate). Initially, in the transformation of 
the h2 SNP − cc estimate to the liability scale (Equation 1) we assumed K = 0.20 for females 
and K = 0.10 for males (Table 2), consistent with literature reports that MDD is twice as 
common in females as males (Weissman, Leaf, Holzer, Myers, & Tischler, 1984). The h2 
SNP estimates were smaller for males (range −0.02 to 0.15) than for females (range 0.10 to 
0.23), but given the magnitude of the standard errors, none of the h2 SNP sex differences 
were significantly different for any individual data set. However, meta-analysis of the 
estimates of the four data sets did lead to estimates that were significantly different (Meta-
4 in Table 2; 0.07 in males vs. 0.11 in females, p = 1.6 × 10−6). In addition, h2 SNP estimated 
from the meta-analyzed GWAS results of the four data sets also showed significant 
difference between males and females (0.06 vs 0.08, p = 6.6 × 10−4; Table 2 GWAS-Meta). 
We also meta-analyzed the six h2 SNP values estimated from the genetic covariance 
between pairs of same-sex data sets in bivariate LDSC analysis. As the traits are (presumed 
to be) the same, the genetic covariance is also an estimate of genetic variance (Supporting 
Information Table S3; Table 2 Meta-6). This again showed lower mean estimates for males 
with a significant difference between the sexes (0.07 in males vs 0.10 in females, p = 
0.0012). For completeness, a metaanalysis from all 10 of the estimates is provided (Table 2 
Meta-10); this uses the same data sets as the GWAS-Meta, but the latter uses all the 
information jointly rather than pairwise. Before drawing strong conclusions from these 
results, it is important to recognize that the estimates of h2SNP depend on the choice of the 
lifetime risk estimates (K in Equations 1 and 2) (Figure 2). The point estimates are more 
similar if the same lifetime risk is assumed between the sexes, but it is difficult to justify 
such an assumption, because it is not, at face value, supported by epidemiological data. 
However, since depression maybe underreported in males (Martin, Neighbors, & Griffith, 
2013; Thornicroft et al., 2017), for illustration purposes we could assume the true lifetime 
risk of MDD is the same between the sexes (K = 0.20), but that through underreporting the 
controls are contaminated by 0.10 of cases (Equation 2, u = 0.1). Under these assumptions, 
the h2 SNP estimates are not significantly different between the sexes for any data set 
(Figure 2, Table 2). For completeness, we also estimated X-chromosome SNPheritability 
from the meta-analyzed cohorts for males and females separately. However, the standard 
errors of the estimates were large relative to the h2 SNP estimates (h2 SNP males=0.0025 
(s.e. = 0.06); h2 SNP females=0.0005 (s.e. = 0.03), which meant estimation of the rg between 






4  DISCUSSION 
Heterogeneity in MDD is often discussed, but hard to investigate. In a novel set of analyses, 
we explored the heterogeneity of MDD using genetic data. The first set of analyses 
contrasted 29 PGC cohorts, by estimating their average contribution to estimates of h2 
SNP from repeated random samplings of cohorts selected into GWAS meta-analyses. 
While we found notable differences between cohorts in the h2 SNP contribution estimates 
(Figure 1), these differences could be explained, at least partly, via knowledge of cohort 
ascertainment practices: higher contributions for cohorts ascertained in clinical compared to 
community settings (Figure 1, p = 0.028), higher contribution from a sample known to use 
super-screened controls (nes1), and a trend toward lower contributions from samples that 
used unscreened controls. One conclusion is that known cohort information about case 
ascertainment status could be included usefully in analysis methods to increase power. A 
framework for such an analysis has been proposed (Zaitlen et al., 2012), but in practice the 
necessary parameters relating to cohort specific risks are usually unknown.In the seven 
samples contributing to the published PGC metaanalysis (PGC29, GERA, iPSYCH, UK Biobank, 
deCode, Generation Scotland, 23andMe) (Wray et al., 2018), h2 SNP estimates ranged from 
0.09 to 0.25 and the weighted mean rg for all pairwise combinations was 0.76 (s.e. = 0.03), 
which is significantly different from one. The cohorts had different recruitment strategies 
with ascertainment ranging from self-report to national hospital records. Moreover, even 
within the Wave 1 PGC-MDD research cohorts endorsement proportions of the nine DSMIV 
criteria showed considerable heterogeneity including between cohorts that had similar 
clinical ascertainment strategies (Major Depressive Disorder Working Group of the 
Psychiatric et al., 2013). For example, endorsement rates of 56%, 27%, and 10% were 
recorded for the criterion symptom 4b, hypersomnia nearly every day, for different early 
onset (<30 years) recurrent MDD samples 
(Major Depressive Disorder Working Group of the Psychiatric et al., 2013). Despite the 
heterogeneity, out-of-sample prediction demonstrated that the self-reported 23andMe 
GWAS results explained variance in clinically ascertained cohorts with high significance 
(Wray et al., 2018). Sample size remains the driving force for genetic discovery in MDD. 
Ideally, larger sample sizes should be accompanied by collection of detailed, consistent, and 
longitudinal phenotypic data to enable more precise case and control definitions. 
We also investigated between-sex genetic heterogeneity. Our sex-specific analyses found 
significantly smaller h2 SNP for males than females, a trend replicated in all four data sets, 
and hence was highly significant in the meta-analysis of the four cohort estimates (Table 2 , 
male v1). However, we recognized that the comparisons of h2 SNP between the sexes 
depended on the choice of their respective lifetime risks (Figure 2). For baseline analyses we 
used lifetime risk estimates of K = 0.20 for females and K = 0.10 for males, consistent with a 
2:1 risk for females versus males (Weissman et al., 1984), with higher K values generating 
higher h2 SNP estimates. One explanation for a lower lifetime risk for males could be higher 
rates of underreporting (Martin et al., 2013; Thornicroft et al., 2017). We calculated h2 
SNP in males assuming the same lifetime risk as females, but with incomplete screening of 
controls. Such a hypothetical scenario generated similar estimates of h2 SNP between the 
sexes (Figure 2, Table 2). 
In summary, our analyses demonstrate between-cohort genetic heterogeneity, but this can 
be explained, at least in part, by known factors such as case/control ascertainment. 
Investigation of between sex heterogeneity provided no convincing evidence to support 
genetic differences between the sexes. A robust conclusion is simply that large sample sizes 
will overcome sample heterogeneity as demonstrated in the latest major depression GWAS 
meta-analyses (Howard et al., 2018; Wray et al., 2018). Based on differences in lifetime 
disease risk and differences in heritability, while assuming a similar number of contributing 
risk loci, we previously estimated that sample sizes for GWAS need to be five times bigger 
for MDD than for schizophrenia (SCZ) (Wray et al., 2012). On the one hand, heterogeneity 
between samples may push this estimate higher. On the other hand, the heterogeneity may 
already account for the higher prevalence and lower heritability. The PGC GWAS meta-
analysis for MDD/major depression based on a total effective sample size of 389,083 (Wray 
et al., 2018) identified 44 independent significant loci. This compares to 145 independent 
loci for SCZ from a total effective sample size of 99,863 (Pardiñas et al., 2018), hence 
requiring >12 times the sample size for major depression compared to SCZ per genome-
wide significant locus. However, the relationship between sample size and variant discovery 
is not linear (Wray et al., 2018) and so observing the sample size ratios for discovery will be 
of interest as sample sizes increase. Very large MDD case–control samples will allow novel 
methods to be applied to assess evidence for genetic subsets, and will allow more robust 
conclusions to be drawn about between sex differences. Larger data sets are likely to lead to 
the development of new methods to assess genetic heterogeneity (Han et al., 2016). There 
is a growing interest in machine learning methods (Libbrecht & Noble, 2015) as a strategy to 
identify phenotypically relevant genetic subsets, but cohort heterogeneity must diminish 
their utility, making large electronic health or biobank samples collected and genotyped in a 
uniform way of most value. 
